Immuno-oncological effects of the α2-adrenoceptor agonist dexmedetomidine

Abstract

The α2-adrenergic receptor agonist dexmedetomidine (DEX) exerts context-dependent antitumor effects, with its efficacy influenced by dose, immune cell involvement and combination with immune checkpoint inhibitors. It will be important to understand to which extent DEX and other α2-adrenergic agonists act on α2-adrenergic receptors from cancer and immune cells.

Keywords

• Cancer
• Clonidine
• Immunotherapy
• Macrophages